A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
← catalyst calendarNCT06610526 · readout in 285 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
731actual
Sites
34
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-23 | actual | When the study began enrolling |
| Primary completion | 2027-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Kidney Disease
Intervention
- Drug: Dapagliflozin
Primary outcome
what the primary-completion date above is the date OFTime to the first occurrence of any of the components of the composite: 50% sustained decline in eGFR or Reaching ESRD or CV Death or Renal Death.
measured Up to a median follow-up time of 24 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed